PluriFRA:4DX 25 Days Payable is 717.17 as of Mar. 2026, which is 99% below its 10-year median of 99,797.09. GuruFocus rates FRA:4DX with a GF Score™ of 25/100 and a GF Value™ of €17.84. The stock has 6 warning signs investors should review. Among 705 Biotechnology companies, Pluri ranks better than 79.72% on this metric.
Pluri's average Accounts Payable for the
three
months ended in Mar. 2026 was €0.75 Mil. Pluri's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €0.10 Mil.
Hence, Pluri's Days Payable for the
three
months ended in Mar. 2026 was 717.17.
The historical rank and industry rank for Pluri's Days Payable or its related term are showing as below:
FRA:4DX'
s Days Payable Range Over the Past 10 Years
Min: 489.7 Med: 99797.09 Max: 505707.5
Current: 525.84
During the past 13 years, Pluri's highest Days Payable was 505707.50. The lowest was 489.70. And the median was 99797.09.
FRA:4DX's Days Payable is ranked better than 79.72% of 705
companies
in the Biotechnology industry
Industry Median: 113.36
vs FRA:4DX: 525.84
Pluri's Days Payable
increased
from Mar. 2025 (334.64) to Mar. 2026 (717.17).
It may suggest that Pluridelayed paying its suppliers.
Pluri Days Payable Related Terms
Pluri Days Payable Historical Data
* Premium members only.
The historical data trend for Pluri's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4DX vs MRKR, VYNE, LGVN: Days Payable Comparison
For the Biotechnology subindustry, Pluri's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pluri Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pluri's Days Payable distribution charts can be found below:
* The bar in red indicates where Pluri's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pluri's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pluri (FRA:4DX) has a Days Payable of 717.17 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pluri and its competitors. This is 99% below median its historical median of 99,797.09. Over the past decade, Pluri's Days Payable has ranged from 489.70 to 505,707.50. According to the industry distribution chart, Pluri ranks #143 out of 705 companies in the Biotechnology industry, placing it in the top 20.3%.
Is Pluri's Days Payable too high?
Pluri's current Days Payable of 717.17 is 99% below median its 10-year median of 99,797.09. Over the past 10 years, this metric has ranged from a low of 489.70 to a high of 505,707.50. The Biotechnology industry median Days Payable is 113.36. Pluri's value of 717.17 is 532.6% above this industry median. Based on the distribution chart, Pluri ranks #143 out of 705 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pluri has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Pluri's Days Payable compare to MRKR and VYNE?
According to the Biotechnology industry distribution chart, Pluri ranks #143 out of 705 companies for Days Payable. This places Pluri in the top 20% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.36. Pluri's value of 717.17 is 532.6% above this benchmark. Historically, Pluri's own Days Payable has ranged from 489.70 to 505,707.50 over the past decade. While the company's 10-year median is 99,797.09 vs. the industry median of 113.36, Pluri has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pluri's current Days Payable of 717.17 is 532.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pluri and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pluri's current Days Payable is 717.17, which is 99% below median its own 10-year median of 99,797.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Pluri (FRA:4DX) has a current Days Payable of 717.17. The stock's GF Value™ is €17.84, compared to a current price of €5.60 — trading 68.6% below its estimated fair value. The current Days Payable is 717.17, which is 99% below median its 10-year median of 99,797.09 and 532.6% above the Biotechnology industry median of 113.36. Pluri's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pluri (FRA:4DX), the current Days Payable is 717.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pluri (FRA:4DX) Overvalued in 2026?
Based on GuruFocus' analysis, Pluri stock appears to be undervalued.
The current stock price of €5.60 is trading 68.6% below its estimated GF Value™ of €17.84.
Key valuation signals for FRA:4DX:
Days Payable: 717.17 (99% below median its 10-year median of 99,797.09)
GF Value™: €17.84 vs. price of €5.60 (68.6% below fair value)
Industry Position: 532.6% above the Biotechnology median (#143 of 705)
No single metric tells the full story. See the FRA:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score
Get the complete analysis for FRA:4DX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4DX has been successfully added to your 
